Between October 1989 and February 1997, 13 patients with refractory or relapsed seminomas were treated with high-dose chemotherapy (HDCT) as part of consecutive phase I/II studies. Six patients had failed prior cisplatin-based first-line treatments and seven patients had also failed cisplatin-based salvage treatments. After The majority of seminoma patients presenting with stage I or nonbulky stage II disease will be cured by orchiectomy with or without retroperitoneal radiotherapy.
The majority of seminoma patients presenting with stage I or nonbulky stage II disease will be cured by orchiectomy with or without retroperitoneal radiotherapy. 1 Only patients with bulky stage II or stage III seminomas are treated with three to four cycles of cisplatin-based combination regimens identical to the ones used in metastatic non-seminomatous germ cell tumors (NSGCT). 1, 2 Cisplatin-based firstline chemotherapy will cure 86% of patients in the good prognosis and 72% of patients in the intermediate prognosis category according to the IGCCCG classification. 3 The optimal salvage strategy in seminoma patients who fail cisplatin-based first-line treatment is unknown. Further conventional-dose chemotherapy as well as high-dose chemotherapy (HDCT) are both highly effective, but HDCT is more toxic and might possibly be delayed for second or subsequent salvage attempts. [4] [5] [6] Correspondence: Dr J Beyer, Klinik für Innere Medizin, mit Schwerpunkt Hämatologie/Onkologie, Klinikum der Philipps Universität, Baldingerstrasse, 35033 Marburg, Germany Received 28 November 2000; accepted 7 May 2002 We retrospectively analyzed response rates and survival in 13 patients with relapsed seminoma who received HDCT plus autologous stem cell reinfusion as first or subsequent salvage treatment.
Patients and methods

Patient characteristics
Between October 1989 and February 1997, 196 patients with relapsed or refractory germ cell tumors (GCT) were included into consecutive clinical trials. In the initial studies 150 patients were treated with conventional doses of cisplatin, etoposide and ifosfamide (PEI) followed by a single cycle of HDCT with carboplatin, etoposide and ifosfamide (CEI). In a subsequent study 46 patients received conventional doses of cisplatin, ifosfamide and paclitaxel (TIP) followed by a single cycle of HDCT with carboplatin, etoposide and thiotepa (CET). 7, 8 In this series, 13/196 patients (7%) had histologically confirmed seminoma. HDCT was used only in patients who had failed prior cisplatin-based treatments. Elevations of human chorionic gonadotropin (HCG) serum levels of less than 1000 U/l were still considered consistent with the diagnosis of pure seminoma. However, serum levels of alphafetoprotein (AFP) had to be normal. Relapses were either radiologically confirmed by increasing tumor manifestations plus histological proof of pure seminoma or by unequivocally increasing serum levels of lactate dehydrogenase (LDH). HDCT was given as intensification of first salvage treatment in six patients and seven patients received HDCT as part of a second salvage attempt.
One patient was initially misdiagnosed with non-Hodgkin's lymphoma and treated with non-cisplatin-based chemotherapy. Because of progressive disease (PD) he was rebiopsied, correctly diagnosed and achieved a partial remission (PR) after five cycles of PEI. Six months later he progressed again and was treated with HDCT. All other patients were diagnosed with and treated as pure seminomas. Details of further patient characteristics are shown in Table 1 .
Treatment and supportive care
Details of the respective treatment protocols and the supportive care have been previously reported. 7, 8 As conven- (CEI; n = 8 patients) or thiotepa 450 mg/m 2 (CET; n = 5 patients) was given. Two patients received bone marrow and 11 patients received PBPC as autologous stem cell rescue after HDCT. Bone marrow was harvested from both posterior iliac crests using standard harvesting techniques. PBPC were collected by standardized automated procedures. All products were cryopreserved for storage as described previously. 7, 8 Patients were hospitalized for HDCT and nursed in single rooms with protective reversive isolation until full neutrophil recovery. Details of further supportive care measures have been described in detail elsewhere. 7, 8 Toxicities were graded according to modified WHO criteria.
All patients are evaluable for toxicity, However, as one patient died from treatment-related toxicity 17 days after HDCT, only 12 patients are available for response.
Definitions
A complete remission (CR) was defined as complete normalization of all radiologic manifestations as well as normalization of the serum tumor markers HCG and LDH.
Patients with a decrease of Ͼ50% of the tumor masses and normal determinations for HCG and AFP were considered to have a partial remission (PR). Progessive disease was defined as an increase of serum markers and/or an increase of the tumor masses of at least 25% or the appearance of any new radiologic tumor manifestations.
Follow-up
Routine follow-up evaluations were performed at 6 and 12 weeks after HDCT consisting of physical and neurologic examinations, computerized tomography scans, and routine chemistry profiles including determination of the serum tumor markers HCG and LDH. Additional examinations were performed as clinically indicated. Thereafter, patients were reevaluated every 3 months during the first year and every 6 months during subsequent years.
Statistical analysis
The probabilities for failure-free and overall survival were calculated according to the method of Kaplan and Meier. 9 The overall survival time lasted from the date of stem cell reinfusion to the date of death or the last follow-up evaluation. The failure-free survival time was calculated from the date of stem cell reinfusion until the date of treatment failure as defined by disease progression, relapse or death from any cause; whichever occurred first. Calculations were performed on a personal computer using the PRISM statistical software (GraphPad Software, San Diego, CA, USA).
Results
Patient characteristics
Details of the patient characteristics at study entry are shown in Table 1 . All patients had failed cisplatin-based first-line or salvage treatment. Extragonadal primary tumors were present in three patients, radiotherapy was used as part of the initial treatment in seven patients.
Response and long-term survival
Among 12 patients who were evaluable for response after HDCT, three patients achieved a CR after HDCT and one additional patient had residual tumor resected which showed necrosis only (NED). Two patients relapsed from CR/NED after 4 and 6 months and both died within 1 year. A PR was obtained as best response after HDCT in 4/12 patients. Among these latter patients, one patient progressed after 6 months and died 12 months after HDCT. UPN = unique patient number; Maximal response = maximal response to any treatment prior HDCT; Max. resp. duration = maximal response duration to any treatment prior HDCT; NPVM = non-pulmonary visceral metastases; HDCT = high-dose chemotherapy; retrop. = retroperitoneal; CBCDA = carboplatin; PEB = cisplatin/etoposide/bleomycin; PEI = cisplatin/etoposide/ifosfamide; VeIP = vinblastine/ifosfamide/cisplatin; PE = cisplatin/etoposide; PEI/CEI = cisplatin/etoposide/ifosfamide followed by high-dose carboplatin/etoposide/ifosfamide; TIP/CET = paclitaxel/ Ifosfamide/cisplatin followed by high-dose carboplatin/etoposide/thiotepa; CR = complete remission; PR = partial remission; PD = progressive disease; TRD = treatment-related death.
a Cisplatin-based salvage combination.
The remaining three patients are alive without relapse at 47+, 64+ and 106+ months. Another 4/12 patients did not benefit from HDCT and did not even show a partial remission ( Table 2 ). All of these latter patients died within 7 months after HDCT. All patients known to be alive were reevaluated in June 2000 for a median follow-up time of 5.3 years (range 4.0 to 8.9 years). At that time five patients were alive without event after HDCT, two of them in CR and three patients in stable PR lasting longer than 4 years. The probabilities of overall and event-free survival are shown in Figure 1 .
Toxicities
All patients experienced reversible WHO grade 4 hematologic toxicity and required antibiotic treatment for neutropenic fever. WHO grade 3 or 4 nausea and/or mucositis were also observed in all patients. Other nonhematologic tox- Bone Marrow Transplantation icities such as ototoxicity, neurotoxicity, cystitis and the side-effects of the liver, lung, heart and skin were generally mild to moderate and manageable. However, one patient died from multiorgan failure 23 days after initiation of high-dose treatment.
Analysis of clinical indicators for long-term survival
Response rates or survival did not differ among patients who received HDCT as first or as subsequent salvage treatment (Table 2 ). Prior salvage chemotherapy was used in 2/5 (40%) patients with long-term survival and in 4/7 (57%) without long-term survival. The use of prior radiotherapy was similar in 4/5 (80%) patients and 3/7 (42%) patients with and without long-term survival, respectively. Likewise, responses to previous treatments were similar in longterm survivors after HDCT and those who eventually failed HDCT. Among long-term survivors after HDCT 3/5 (60%) patients had achieved a CR as compared to 3/7 (42%) patients who eventually failed. However, both patients with a response duration у10 months prior to HDCT became long-term survivors. Non-pulmonary visceral metastases were present in only 1/5 (20%) patients who eventually became long-term survivors, but in 3/7 (43%) patients who suffered treatment failures.
Immediately prior to HDCT, 10 patients were classified as having good prognosis and three patients as having intermediate prognosis for long-term survival after HDCT using published criteria. 10 Among the good prognosis category, 5/10 (50%) became long-term survivors and one patient died from treatment-related toxicity while being in complete remission. However, all three patients in the intermediate category failed; two were considered to be refractory to cisplatin and all three had progressive disease at the time of HDCT.
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Discussion
Only about 10-20% of seminoma patients who receive cisplatin-based first-line chemotherapy will require further salvage treatment. 1, 4, 6 Miller et al 4 from Indiana University treated 24 seminoma patients who had relapsed after cisplatin-based first-line treatment with further conventional-dose cisplatin, vinblastine and ifosfamide (VeIP). The response to VeIP was excellent with a CR rate of 88% and a projected overall survival of 54% at 7 years. These investigators recommended the use of VeIP as standard first-salvage treatment for seminoma patients who relapse after cisplatin-based first-line chemotherapy and suggested delaying HDCT in case further salvage treatment is required. However, Bhatia et al 5 from the same group investigated HDCT as intensification of first-salvage treatment in 65 patients with NSGCT or seminoma and found an even superior long-term survival rate of 90% among the 10 seminoma patients included. Unfortunately no further details as to pretreatment and follow-up of seminoma patients were provided.
More recently, investigators from the Memorial Sloan Kettering Cancer Center (MSKCC) reported on the salvage treatment of 27 seminoma patients who failed cisplatinbased first-line treatment; 15 patients were treated with conventional-dose cisplatin-based chemotherapy and 12 patients received HDCT as intensifiation of first-salvage treatment. 6 The overall CR rate was 56% and the projected overall survival was 57% at 2 years with no significant differences between either group of patients, although more patients with an incomplete response to first-line treatment were scheduled to receive HDCT. One patient relapsed from CR to conventional-dose salvage treatment and was successfully salvaged by further HDCT. Other reports on HDCT in seminoma patients are scarce.
We analyzed two distinct groups of seminoma patients: six patients received HDCT as intensification of first-salvage treatment and were comparable to the ones reported from Indiana University and the MSKCC. The remaining seven patients had relapsed after cisplatin-based first-salvage treatment and received HDCT as part of a second salvage attempt (Table 2) .
Despite the use of HDCT only 50% of all evaluable patients achieved remissions and only 38% of patients became long-term survivors. One additional patient died in CR from treatment-related toxicity. Response rates and long-term survival did not differ significantly whether or not HDCT was used as first or subsequent salvage treatment. Therefore, our results do not favor the use of HDCT in seminoma patients who fail cisplatin-based first-line treatment. We could demonstrate, however, that HDCT still has curative potential in seminoma patients who relapse after cisplatin-based salvage treatment. Two out of seven patients in the present series remain alive at 47+ and 106+ months.
Although limited by the small number of patients and because of its retrospective nature, it appears from the present analysis that seminoma patients with non-pulmonary visceral metastases, those with short relapse-free intervals and particularly those who have become refractory to cisplatin had less benefit from HDCT irrespective of whether they received HDCT as part of their first or subsequent salvage attempt. Selection of patients with poor prognostic features might also explain the inferior results in the present series compared with previous reports.
In conclusion, high-dose chemotherapy can have curative potential when given as first or subsequent salvage treatment in patients with metastatic seminoma. Prognostic factors might be useful to guide further treatment decisions. Patients with an incomplete response to first-line treatment and those with short relapse-free intervals might profit from early treatment intensification, while refractoriness to cisplatin carries a poor prognosis irrespective of the salvage strategy chosen.
